Enanta Pharmaceuticals, Inc.
Financials
Valuation Metrics
Enanta Pharmaceuticals, Inc.'s Market Cap is $355M. At end of 2025 it was $337M. Ranked #2899 of 3,121 in US market (top 93%), #1297 of 1,463 on NASDAQ (top 89%), #235 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $355M | US#2,899/3,121 Sec#235/266 |
| Revenue | $65M | US#2,754/3,121 Sec#141/266 |
| Net Income | $-63M | US—/3,121 Sec—/266 |
| Total Assets | $297M | US#2,917/3,121 Sec#210/266 |
| Net Assets | $101M | US#2,809/3,121 Sec#216/266 |
| Employees | 120 | US#2,596/3,121 Sec#166/266 |
| Value | ||
| P/B | 3.51x | US#1,918/3,121 Sec#104/266 |
| P/S | 5.44x | US#2,378/3,121 Sec#82/266 |
| FCF Yield | -10.41% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -62.56% | US#2,727/3,121 Sec#177/266 |
| ROA | -21.30% | US#2,812/3,121 Sec#131/266 |
| Op. Margin | -89.99% | US#2,731/3,121 Sec#121/266 |
| Revenue Growth | 0.70% | US#2,194/3,121 Sec#131/266 |
| Financial Health | ||
| Debt Ratio | 193.73% | US#1,768/3,121 Sec#200/266 |
| Total Debt | $56M | US#2,593/3,121 Sec#150/266 |
| FCF | $-37M | US#2,493/3,121 Sec#106/266 |
| Cash | $33M | US#2,731/3,121 Sec#246/266 |
| Current Ratio | 3.76x | US#620/3,121 Sec#169/266 |
| Performance | ||
| 1Y Return | 55.61% | US#385/3,121 Sec#86/266 |
| 1M Return | -9.70% | US#1,871/3,121 Sec#147/266 |
| From 52W High | -28.86% | US#1,894/3,121 Sec#147/266 |
| 1Y MDD | -34.30% | US#1,702/3,121 Sec#112/266 |
| Trading | ||
| Volume | 409,805 shares | US#2,492/3,121 Sec#242/266 |
| Trading Value | $5M | US#2,787/3,121 Sec#237/266 |
| Per Share | ||
| EPS | $-2.17 | US—/3,121 Sec—/266 |
| BPS | $3.48 | US#2,426/3,121 Sec#155/266 |
Company Info
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.